TAK-901

DB12756InvestigationalSmall molecule

TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.

Mechanism: Pharmacologically active on Aurora kinase B
Curator reviewed
Formula / weight: C₂₈H₃₂N₄O₃S · 504.65 g/mol (avg)
Code names: TAK-901

Resolves to

Compound

UNIIDM9UIR23R7CAS934541-31-8ChEMBLCHEMBL3544932PubChem16124208

Structure

InChIKeyWKDACQVEJIVHMZ-UHFFFAOYSA-NSMILESCCS(=O)(=O)C1=CC=CC(=C1)C1=CC(C(=O)NC2CCN(C)CC2)=C(C)C2=C1C1=C(N2)N=CC(C)=C1

Targets

Q96GD4AURKBQ07812BAX

What you can answer from here — as of April 02, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with TAK-901, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account